Tamar Peretz

Primary colorectal sarcoma. A retrospective review and prognostic factor study of 50 consecutive patients.

M. Brennan, T. Peretz, J. Gaynor, 1990, Archives of surgery.

A single-nucleotide polymorphism in the RAD51 gene modifies breast cancer risk in BRCA2 carriers, but not in BRCA1 carriers or noncarriers

R. Eeles, Z. Kote-Jarai, B. Glaser, 2004, British Journal of Cancer.

Microsatellite instability and p53 mutations in therapy-related leukemia suggest mutator phenotype.

S. Ben-Neriah, S. Krichevsky, D. Abeliovich, 1996, Blood.

Autologous cell vaccine as a post operative adjuvant treatment for high-risk melanoma patients (AJCC stages III and IV)

T. Peretz, M. Lotem, D. Prus, 2002, British Journal of Cancer.

The Jewish Ashkenazi founder mutations in the BRCA1/BRCA2 genes are not found at an increased frequency in Ashkenazi patients with prostate cancer.

O. Manor, I. Lerer, D. Abeliovich, 1999, American journal of human genetics.

Ovarian cysts in premenopausal and postmenopausal tamoxifen-treated women with breast cancer.

S. Mor-Yosef, T. Peretz, B. Uziely, 1996, American journal of obstetrics and gynecology.

CAG and GGC repeat polymorphisms in the androgen receptor gene and breast cancer susceptibility in BRCA1/2 carriers and non-carriers

R. Eeles, Z. Kote-Jarai, S. Edwards, 2001, British Journal of Cancer.

Tumor suppressor p53 regulates heparanase gene expression

Y. Haupt, T. Peretz, I. Vlodavsky, 2006, Oncogene.

A clinical evaluation of an ex vivo organ culture system to predict patient response to cancer therapy

R. Berger, A. Zick, H. Nechushtan, 2023, Frontiers in medicine.

Therapeutic approach to ovarian cysts in tamoxifen‐treated women with breast cancer

S. Mor-Yosef, T. Peretz, A. Shushan, 1996, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

Interleukin-2 improves tumour response to DNP-modified autologous vaccine for the treatment of metastatic malignant melanoma

T. Peretz, M. Lotem, E. Shiloni, 2004, British Journal of Cancer.

Prognostic role of serum cytokeratin 19 fragments in advanced non-small-cell lung cancer: association of marker changes after two chemotherapy cycles with different measures of clinical response and survival

T. Peretz, V. Barak, H. Biran, 2007, British Journal of Cancer.